Peter Libby, MD, is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis, with a particular devotion to translate his basic laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials.

Dr. Libby is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron.

Dr. Libby is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, Soley Thereapeutics, TenSixteen Bio, and XBiotech, Inc.

Dr. Libby’s laboratory has received research funding in the last 2 years from Novartis.

Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies. Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.

Dr. Peter Libby has a financial interest in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.

Funding

Dr. Libby receives funding support from the National Heart, Lung, and Blood Institute (1R01HL134892 and 1R01HL163099), the American Heart Association (18CSA34080399), the RRM Charitable Fund, and the Simard Fund.

Patents

Ridker P, Thuren T, Bermann G, Libby P, inventors; Brigham and Women’s Hospital, assignee. Use of Canakinumab. United States Patent Application 20200239564. 2020 Aug 18. 5409-0001; U.S. Provisional Patent Application for “Treatment of Brain Ischemia-Reperfusion Injury”.